REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
Carhart-Harris, R. L., & Friston, K. J. | Pharmacological reviews | 20 June 2019
Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Dowling, G., ... & Halberstadt, A. L. | Drug testing and analysis | 18 June 2018
Motives and side-effects of microdosing with psychedelics among users
Hutten, N. R., Mason, N. L., Dolder, P. C., & Kuypers, K. P. | International Journal of Neuropsychopharmacology | 31 May 2019
Palliative Nursing and Sacred Medicine: A Holistic Stance on Entheogens, Healing, and Spiritual Care.
Rosa, W. E., Hope, S., & Matzo, M. | Journal of Holistic Nursing | 18 April 2018
A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., ... & Páleníček, T. | Psychopharmacology | 13 April 2019
Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers.
Baggott, M. J., Garrison, K. J., Coyle, J. R., Galloway, G. P., Barnes, A. J., Huestis, M. A., & Mendelson, J. E. | Journal of psychoactive drugs | 9 April 2019
Classic psychedelics: the special role of the visual system
Császár-Nagy, N., Kapócs, G., & Bókkon, I. | Reviews in the neurosciences | 2 April 2019
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R.| The American journal of drug and alcohol abuse | 1 March 2019
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers
Erritzoe, D., Smith, J., Fisher, P. M., Carhart-Harris, R., Frokjaer, V. G., & Knudsen, G. M.| Journal of Psychopharmacology | 28 February 2019
Long-lasting analgesic effect of the psychedelic drug changa: A case report
Ona, G., & Troncoso, S. | Journal of Psychedelic Studies |12 February 2019
The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis
Argento, E., Tupper, K. W., & Socias, M. E. | International Journal of Drug Policy | 7 February 2019
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. | PloS one | 6 February 2019
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., ... & Pogarell, O. | European archives of psychiatry and clinical neuroscience | 31 January 2019
Neurochemical models of near-death experiences: A large-scalestudy based on the semantic similarity of written reports
Martial, C., Cassol, H., Charland-Verville, V., Pallavicini, C., Sanz, C., Zamberlan, F., & Tagliazucchi, E. | Consciousness and cognition | 20 January 2019
Transformative Psychopharmacology: the Case of 5-Methoxy-N,N-Dimethyltryptamine
Jan M Keppel Hesselink | International Journal of Psychotherapy Practice and Research | 2 January 2019
How do psychedelics work?
Carhart-Harris, R. L. | Current opinion in psychiatry | 1 January 2019
DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens
Lakstygal, A., Kolesnikova, T., Khatsko, S., Zabegalov, K., Volgin, A., Demin, K., & Kalueff, A. | ACS chemical neuroscience | 19 December 2018
A Jamesian Response to Reductionism in the Neuropsychology of Religious Experience
Kime, K. G., & Snarey, J. R. | Archive for the Psychology of Religion | 13 December 2018
Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence
Knuijver, T., Belgers, M., Markus, W., Verkes, R. J., van Oosteren, T., & Schellekens, A. | Journal of clinical psychopharmacology | 1 December 2018
Self-Experiments with Psychoactive Substances: A Historical Perspective
Passie, T., & Brandt, S. D. | Handbook of Experimental Pharmacology | 27 November 2018
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Garcia-Romeu, A., & Richards, W. A. | International Review of Psychiatry | 13 November 2018
The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines
Zamberlan, F., Sanz, C., Martinez Vivot, R., Pallavicini, C., Erowid, E., & Tagliazucchi, E. | Frontiers in integrative neuroscience | 8 November 2018
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. | Progress in brain research | 25 October 2018
Psychedelic Moral Enhancement
Earp, B. D. | Royal Institute of Philosophy Supplements | 16 October 2018
Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.
Kivell, B., Paton, K., Kumar, N., Morani, A., Culverhouse, A., Shepherd, A., ... & Prisinzano, T. | Molecules | 11 October 2018